For patients with a common form of lung cancer, a new treatment option arrived in the United States on August 15, 2024. The drug, known as Lazertinib and sold under brand names including Lazcluze and Leclaza, is now cleared for medical use. It targets non-small cell lung cancer, a disease that accounts for the vast majority of lung cancer diagnoses.
Lazertinib works by blocking a specific protein called the epidermal growth factor receptor. This receptor, when active, can drive cancer cells to grow and spread. By inhibiting it, the drug aims to slow or stop that growth. The approval follows years of clinical development and an earlier green light in South Korea, where the medication has been available since January 2021.
The side effect profile is substantial. Patients treated with Lazertinib commonly experience rash, nail toxicity, and infusion-related reactions. Musculoskeletal pain, edema, and stomatitis are also frequent. The list includes venous thromboembolism, paresthesia, fatigue, diarrhea, constipation, and COVID-19 infection. Hemorrhage, dry skin, decreased appetite, pruritus, nausea, and ocular toxicity round out the adverse reactions. These risks mean doctors will need to monitor patients closely, managing symptoms as they arise.
The approval matters because non-small cell lung cancer remains a leading cause of cancer death. Treatment options have expanded in recent years, but the disease still claims hundreds of thousands of lives annually. Lazertinib adds another tool—one that attacks a specific molecular target. For patients whose tumors harbor mutations in the epidermal growth factor receptor, this drug could make a real difference.
What comes next is the real-world rollout. Hospitals and clinics must decide how to integrate Lazertinib into existing treatment protocols. Insurers will set coverage policies. Patients and oncologists will weigh the benefits against the side effects. The drug’s performance in broader populations, outside the controlled environment of clinical trials, will become clear only with time.
South Korea’s earlier approval offers some clues. Since January 2021, Korean physicians have gathered experience with the drug. That data, while not a perfect predictor, suggests how the medication might behave in American patients. The U.S. approval was likely informed by that international track record.
Lazertinib belongs to a class of drugs known as kinase inhibitors. These medicines have transformed the treatment of certain cancers, turning some lethal diseases into chronic conditions. But they are not cures, and resistance often develops. The cancer adapts, finding new pathways to grow. Researchers are already studying combinations and next-generation drugs to stay ahead.
For now, the immediate effect is simple: a new option exists. Patients who might have exhausted other therapies now have something else to try. The approval does not mean the drug will work for everyone, and the side effects are real. But for a subset of patients with non-small cell lung cancer, Lazertinib represents a chance at more time.
The Food and Drug Administration’s decision on August 15 ended years of waiting. It also began a new phase: the slow, careful work of bringing the drug to the people who need it. That process will unfold in doctors’ offices, pharmacy shelves, and insurance negotiations across the country.
